<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00008437</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068417</org_study_id>
    <secondary_id>TXS-G990184</secondary_id>
    <secondary_id>DFCI-99029</secondary_id>
    <secondary_id>MDA-ID-99137</secondary_id>
    <secondary_id>TXS-1999-P-009925/10</secondary_id>
    <secondary_id>NCI-V00-1643</secondary_id>
    <nct_id>NCT00008437</nct_id>
  </id_info>
  <brief_title>MRI-Guided Ultrasound Energy in Treating Patients With Stage I, Stage II, or Stage IIIA Breast Cancer</brief_title>
  <official_title>Pilot Study of MR-Guided Focused Ultrasound for Tissue Coagulation in Women With Breast Cancer: MR Imaging and Histopathic Correlation, An Assessment or Target Accuracy and Patient Acceptance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSightec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSightec</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Imaging procedures, such as MRI, may allow the doctor to better detect the tumor.&#xD;
      Highly focused ultrasound energy may be able to kill tumor cells by heating the breast tumor&#xD;
      cells without affecting the surrounding tissue.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of MRI-guided ultrasound energy in&#xD;
      treating women who have stage I, stage II, or stage IIIA breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the incidence and severity of adverse events during and after MRI-guided&#xD;
           focused ultrasound ablation in women with stage I-IIIA breast cancer.&#xD;
&#xD;
        -  Determine the ability to accurately and thoroughly coagulate a target volume of breast&#xD;
           carcinoma, in terms of real-time target volume temperature profile, follow-up MRI, and&#xD;
           histology, using this procedure.&#xD;
&#xD;
        -  Compare the appearance of gross and microscopic histopathologic tissue post coagulation&#xD;
           with the pre- and post-coagulation magnetic resonance appearance of the targeted volume&#xD;
           and measure any residual cancer cells in patients after this procedure.&#xD;
&#xD;
        -  Determine patient acceptance of this procedure, in terms of positioning, pain, safety,&#xD;
           and follow-up cosmesis.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
      Patients undergo MRI-guided focused ultrasound (MRgFUS) ablation of the breast lesion using a&#xD;
      series of pulses. Within 72 hours after MRgFUS procedure, patients undergo&#xD;
      gadolinium-enhanced MRI to evaluate ablation borders. Within 7-10 days after MRgFUS&#xD;
      procedure, patients undergo an ultrasound exam. Guide wires may be placed to assist in&#xD;
      pre-surgical lesion localization. Within 10-21 days after MRgFUS procedure, patients undergo&#xD;
      segmental resection or mastectomy.&#xD;
&#xD;
      Patients are followed at 5-10 days post-surgery.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 45 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2000</start_date>
  <completion_date type="Actual">December 2000</completion_date>
  <primary_completion_date type="Actual">December 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>high-intensity focused ultrasound ablation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed invasive breast cancer (T1, N0-2, M0)&#xD;
&#xD;
          -  Single focal lesion no greater than 3.5 cm in diameter by MRI&#xD;
&#xD;
          -  No lesions difficult to target, defined as less than 1 cm from skin, nipple, or rib&#xD;
             cage&#xD;
&#xD;
          -  No microcalcifications as sole sign of disease&#xD;
&#xD;
          -  No extensive intraductal components on core biopsy, defined as intraductal carcinoma&#xD;
             comprising 25% or more of the invasive breast cancer AND intraductal carcinoma in&#xD;
             surrounding normal tissue&#xD;
&#xD;
          -  No breast implants&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 80-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 5 years&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  No hemolytic anemia (hematocrit less than 30%)&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No heart disease&#xD;
&#xD;
          -  No unstable angina pectoris requiring medication&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No congestive heart failure requiring medication&#xD;
&#xD;
          -  No diastolic blood pressure greater than 100 mm Hg while receiving medication to treat&#xD;
             hypertension&#xD;
&#xD;
          -  No cerebrovascular accident (CVA) within the past 6 months&#xD;
&#xD;
          -  No multiple CVAs&#xD;
&#xD;
          -  No cardiac pacemakers&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No chronic obstructive pulmonary disease&#xD;
&#xD;
          -  No other lung disease&#xD;
&#xD;
          -  No sleep apnea or airway problems&#xD;
&#xD;
          -  No severe asthma&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No contraindications to MRI (e.g., implanted medical devices)&#xD;
&#xD;
          -  Must be able to lie prone and still for up to 150 minutes&#xD;
&#xD;
          -  Weight no greater than 250 pounds&#xD;
&#xD;
          -  No severe arthritis&#xD;
&#xD;
          -  No severe claustrophobia&#xD;
&#xD;
          -  No grand mal seizures&#xD;
&#xD;
          -  No insulin-dependent diabetes mellitus&#xD;
&#xD;
          -  No prior reaction to gadolinium-based contrast agent&#xD;
&#xD;
          -  Able to communicate sensations during procedure&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 months since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Concurrent hormone replacement therapy allowed&#xD;
&#xD;
          -  Concurrent tamoxifen allowed&#xD;
&#xD;
          -  No concurrent steroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior external radiotherapy or laser therapy to ipsilateral breast&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent anti-arrhythmic drugs&#xD;
&#xD;
          -  No concurrent immunosuppressive medication&#xD;
&#xD;
          -  No concurrent anticoagulation therapy&#xD;
&#xD;
          -  No concurrent dialysis&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert W. Newman</last_name>
    <role>Study Chair</role>
    <affiliation>InSightec</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM Hopital Saint-Luc</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>January 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 29, 2012</last_update_submitted>
  <last_update_submitted_qc>June 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

